ESTRO 2024 - Abstract Book

S1636

Clinical - Lung

ESTRO 2024

2 year-OS was 62% with a median follow-up of 25 months (8-48 months). The median follow up for local control and toxicity was 13 Months (3-45 Months). The estimated 2-Year local control rate was 96%.

Toxicity was overall low. At baseline before therapy dyspnoea grade 1/2/3 was reported in 28%/56%/16% of patients. The respective rates were 23%/53%/23% at 1 year following after therapy. No grade 4 or 5 toxicity were reported. Cough was reported at baseline with grade 1/2 /3 by 44%/20/0% of all patients, and at 1 year with 10%/0%,0% respectively. In the per patients analysis none of the patients showed clinically significant increase of toxicity.

Conclusion:

In this patient cohort, SBRT has proven to be a safe and effective treatment option in patients with severely reduced pulmonary function. Longer follow up and a larger patient population are needed to validate these findings.

Keywords: SBRT pulmonary function

953

Digital Poster

Safety and efficacy of Pirfenidone in prevention of RT induced pneumonitis in Lung cancer patients

Naveen Mummudi, Sam David, Anil Tibdewal, Sandeep Tandon, Jai Prakash Agarwal

Tata Memorial Hospital, Radiation Oncology, Mumbai, India

Purpose/Objective:

A significant proportion of patients undergoing radical radiation therapy (RT) for lung cancer develop clinico radiological features of radiation pneumonitis (RP), which can compromise their survival outcomes. We conducted an open label, single arm, phase II study to evaluate the efficacy of Pirfenidone (PFD), a synthetic pyridone compound in the prevention of radiation induced fibrosis.

Material/Methods:

Patients with lung cancer who were candidates for radical radiation therapy with or without chemotherapy were administered PFD orally 1 week before starting RT at a starting dose of 600mg/day and increased to 1200mg/day, if tolerating well. PFD was be given for the entire duration of RT and continued for 10 weeks after RT completion. PFTs was performed at baseline and repeated at first follow-up and then every 6 months. Patients were imaged at baseline and at follow-up with PET CT/CT scans as per routine institutional imaging protocol. Primary endpoints were change in pulmonary function tests (PFT) at 3- and 6-months post radiation compared to pre-RT values.